Diagnostic and Predictive Biomarkers in Lung Cancer

Related Experiment Video

Updated: Nov 3, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.9K

Caterina Fumagalli1, Massimo Barberis1

  • 1Division of Pathology, IEO, European Institute of Oncology, IRCCS, 20141 Milano, Italy.

Cancers
|June 2, 2021
PubMed

Abstract:

Lung cancer is the most frequent cause of cancer-related mortality worldwide [...].

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K

Related Experiment Videos

Last Updated: Nov 3, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K

Articles linked to this work by shared authors, journal, and citation graph.

Characterization of a Genetic Variant in BARD1 in Subjects Undergoing Germline Testing for Hereditary Tumors.

Biomedicines·2025

GPNMB marks a quiescent cell population in melanoma and promotes metastasis formation.

EMBO reports·2025

A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report.

Translational lung cancer research·2025

A Transcriptomic Analysis of Laryngeal Dysplasia.

International journal of molecular sciences·2024

Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients.

Cancers·2023

Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience.

Genes·2023

Correction: Schöbel et al. Non-Cisplatin Concurrent Systemic Therapy with Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Network Meta-Analysis of Randomized Clinical Trials. Cancers 2026, 18, 1599.

Cancers·2026

Correction: García-Delgado et al. Translational Insights into Interferon Alpha's Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms. Cancers 2025, 17, 2273.

Cancers·2026

Correction: Volkova et al. Anaplastic Large Cell Lymphoma in Children: 20-Year Immune-Oriented Treatment Experience. Cancers 2026, 18, 1583.

Cancers·2026

Correction: Zaffalon et al. Dilemmas in the Clinical Management of pT1 Colorectal Cancer. Cancers 2023, 15, 3511.

Cancers·2026

Correction: Kania et al. Evaluating the Transition from 3D Laparoscopy to Robotic Partial Nephrectomy: Trifecta Achievement and Nephrometry Score Differences. Cancers 2025, 17, 3976.

Cancers·2026

Correction: Kühn et al. HPV Status as Prognostic Biomarker in Head and Neck Cancer-Which Method Fits the Best for Outcome Prediction? Cancers 2021, 13, 4730.

Cancers·2026

Histopathological predictors of extranodal extension in oral cavity squamous cell carcinoma: a five-year retrospective cohort study.

The British journal of oral & maxillofacial surgery·2026

Impact of Preoperative Sarcopenia on Survival and Perioperative Outcomes After Radical Cystectomy for Bladder Cancer.

Clinical genitourinary cancer·2026

The immune code of metal-dependent cell death.

Trends in immunology·2026

Weight Loss, FVC Decline, and Composite Physiologic Index as Complementary Prognostic Indicators in Idiopathic Pulmonary Fibrosis over the Disease Course: Time-Updated and Landmark Analysis.

Archivos de bronconeumologia·2026

Development and Internal Validation of the RMC-COMPASS Clinical Prognostic Model for SMARCB1-deficient Renal Medullary Carcinoma.

European urology oncology·2026

Preoperative Prediction of Lymph Node Metastasis in Rectal Cancer Using Multimodal Magnetic Resonance Imaging Radiomics Combined with Clinical Risk Factors.

Academic radiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us